Lymphoma in acquired generalized lipodystrophy

Acquired generalized lipodystrophy (AGL) is a rare disease thought to result from autoimmune destruction of adipose tissue. Peripheral T-cell lymphoma (PTCL) has been reported in two AGL patients. We report five additional cases of lymphoma in AGL, and analyze the role of underlying autoimmunity and recombinant human leptin (metreleptin) replacement in lymphoma development. Three patients developed lymphoma during metreleptin treatment (two PTCL and one ALK-positive anaplastic large cell lymphoma), and two developed lymphomas (mycosis fungoides and Burkitt lymphoma) without metreleptin. AGL is associated with high risk for lymphoma, especially PTCL. Autoimmunity likely contributes to this risk. Lymphoma developed with or without metreleptin, suggesting metreleptin does not directly cause lymphoma development; a theoretical role of metreleptin in lymphoma progression remains possible. For most patients with AGL and severe metabolic complications, the proven benefits of metreleptin on metabolic disease will likely outweigh theoretical risks of metreleptin in lymphoma development or progression.

[1]  L. Medeiros,et al.  ALK-Positive Anaplastic Large Cell Lymphoma , 2013 .

[2]  D. Savage,et al.  Acquired generalized lipodystrophy associated with peripheral T cell lymphoma with cutaneous infiltration , 2015, International journal of dermatology.

[3]  F. Casanueva,et al.  Recombinant human leptin treatment in genetic lipodystrophic syndromes: the long-term Spanish experience , 2014, Endocrine.

[4]  K. Hemminki,et al.  Autoimmune diseases associated with non-Hodgkin lymphoma: a nationwide cohort study. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  W. Klapper,et al.  ALK-positive anaplastic large cell lymphoma limited to the skin: clinical, histopathological and molecular analysis of 6 pediatric cases. A report from the ALCL99 study , 2013, Haematologica.

[6]  J. Vose,et al.  Epidemiology and Prognosis of T-Cell Lymphoma , 2013 .

[7]  J. Chan,et al.  Clinical effects of long-term metreleptin treatment in patients with lipodystrophy. , 2011, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[8]  A. Garg.  Lipodystrophies: Genetic and Acquired Body Fat Disorders , 2011 .

[9]  Kenneth G. C. Smith,et al.  Complement abnormalities in acquired lipodystrophy revisited. , 2009, The Journal of clinical endocrinology and metabolism.

[10]  P. Gorden,et al.  Efficacy of leptin therapy in the different forms of human lipodystrophy , 2009, Diabetologia.

[11]  X. Mariette,et al.  Autoimmune and inflammatory disorders and risk of malignant lymphomas – an update , 2008, Journal of internal medicine.

[12]  J. Cerhan,et al.  Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. , 2008, Blood.

[13]  P. Blackshear,et al.  Predictors of Acquired Lipodystrophy in Juvenile-Onset Dermatomyositis and a Gradient of Severity , 2008, Medicine.

[14]  P. Gorden,et al.  Long-term efficacy of leptin replacement in patients with Dunnigan-type familial partial lipodystrophy. , 2007, Metabolism: clinical and experimental.

[15]  T. Kusakabe,et al.  Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy. , 2007, The Journal of clinical endocrinology and metabolism.

[16]  J. Yiannias,et al.  Peripheral T‐cell lymphoma presenting as lipoatrophy and nodules , 2006, International journal of dermatology.

[17]  S. Holland,et al.  Leptin replacement therapy modulates circulating lymphocyte subsets and cytokine responsiveness in severe lipodystrophy. , 2006, The Journal of clinical endocrinology and metabolism.

[18]  A. Garg.  Acquired and inherited lipodystrophies. , 2004, The New England journal of medicine.

[19]  M. Kadin.  Peripheral T Cell Lymphoma, NOS , 2003 .

[20]  A. Garg,et al.  Clinical Features and Metabolic Derangements in Acquired Generalized Lipodystrophy: Case Reports and Review of the Literature , 2003, Medicine.

[21]  Y. Matsuzawa,et al.  Serum adiponectin and leptin levels in patients with lipodystrophies. , 2004, The Journal of clinical endocrinology and metabolism.

[22]  Y. Matsuzawa,et al.  Serum adiponectin and leptin levels in patients with lipodystrophies , 2002 .

[23]  M. Reitman,et al.  Leptin-replacement therapy for lipodystrophy. , 2002, The New England journal of medicine.

[24]  R. Braylan,et al.  LYMPHOHISTIOCYTIC ANAPLASTIC LARGE CELL LYMPHOMA STAGE I: Long-Term Survival after Resection Alone , 2000, Pediatric hematology and oncology.

[25]  J Licinio,et al.  Human leptin deficiency caused by a missense mutation: multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defe , 1999, The Journal of clinical endocrinology and metabolism.

[26]  A. Hübler,et al.  Dysregulation of insulin-like growth factors in a case of generalized acquired lipoatrophic diabetes mellitus (Lawrence Syndrome) connected with autoantibodies against adipocyte membranes. , 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[27]  Stephen R. Bloom,et al.  Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression , 1998, Nature.

[28]  O. Mioduszewska,et al.  T-cell lymphomas. , 2018, Archiv fur Geschwulstforschung.

[29]  S. Hall,et al.  Generalized lipodystrophy, scleroderma, and Hodgkin's disease. , 1978, Archives of internal medicine.

[30]  John McGrath,et al.  Hodgkin’s Disease , 1933, JAMA.